Villepinte (France), December 17, 2020 (8:00 a.m. CET) – Guerbet (FR0000032526 GBT), a world leader in medical imaging, received an A- rating for its second participation in the CDP Climate Questionnaire, a non-profit organization that distinguishes the world's most active companies in the fight against climate change, improving its score from last year (B).
The CDP's annual environmental performance reporting and rating process is a benchmark for corporate environmental transparency. In 2020, more than 515 investors with assets of more than $106 trillion and more than 150 acquirers with $4 trillion in assets called on organizations to share their environmental impact and opportunities and risks and opportunities through the CDP platform.
"As we celebrate the fifth anniversary of the Paris Agreement, we are very pleased that our commitment and progress is being recognized by the CDP. Guerbet continues its dynamic CSR approach, a real lever of performance and a differentiator, under the historical impetus of family shareholders. We are committed to reducing our environmental footprint and engaging our ecosystem in a virtuous circle of decarbonization," comments Petra Zalabak, Guerbet's Director of Human Resources and CSR.
Guerbet's CSR approach is based on four axes with key objectives and actions by 2023. One of the main areas is the HSE policy, which gives top priority to the safety of people and also aims to minimize environmental impacts at all levels.
Through its HSE policy, Guerbet is committed to implementing solutions aimed at preserving the environment through the performance of industrial facilities and actions aimed at limiting their environmental impacts:
Guerbet is also committed to implementing actions to reduce its impact on global warming.
On its key programming positions, the Group:
 CDP: Carbon Disclosure Project. Disclosure Insight Action.
At Guerbet, we build lasting relationships so that we enable people to live better. This is our purpose. We are a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging. A pioneer since 95 years in the field of contrast media with over 2,600 people globally, we are continuously innovating with 10% of revenue dedicated to Research & Development and four centers in France, Israel and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €712 million in revenue in 2020. For more information, please visit www.guerbet.com
+33 (0)6 64 18 99 59